Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

Alzheimer's Disease

Interventions

DRUG

Placebo

Commercially available 0.9% isotonic sodium chloride solution.

BIOLOGICAL

octagam 10%

octagam 10% was supplied as ready-to-use solutions of human immunoglobulin.

Trial Locations (1)

Octapharma USA, Hoboken